Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

3,4-dihydroxybenzohydroxamic acid

Known as: Benzamide, N,3,4-trihydroxy-, Didox, N,3,4-trihydroxybenzamide 
A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Antineoplastic AgentsEnzyme InhibitorsHydroxamic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact.
Axonal pathology is a key contributor to long-term disability in multiple sclerosis (MS), an inflammatory demyelinating disease… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity
Doxorubicin (DOX) has limited efficacy in colorectal cancer due to multi-drug resistance. Resveratrol (RES) and didox (DID) are… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages.
Didox (3,4-dihydroxy-benzohydroxamic acid), is a synthetic ribonucleotide reductase (RR) inhibitor derived from polyhydroxy… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
2013
2013
Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.
Ganciclovir (GCV) is a deoxyguanosine analog that is effective in inhibiting human cytomegalovirus (HCMV) replication. In… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation.
OBJECTIVE Clinically, the vascular pathobiology of human sickle cell disease includes an abnormal state of chronic inflammation… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants
Objective: To determine the role of oxidative stress in mediating HIV dementia and to identify novel therapeutic compounds that… Expand
  • figure 2
  • figure 1
  • figure 5
  • figure 6
Is this relevant?
2003
2003
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells
PurposeTemozolomide (TMZ), an oral alkylating agent with good penetration of the blood-brain barrier, has shown efficacy in the… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2001
2001
Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.
OBJECTIVE Amidox and didox are two polyhydroxy-substituted benzohydroxamic acid derivatives that belong to a new class of… Expand
Is this relevant?
1999
1999
In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
Inhibitors of the cellular enzyme ribonucleotide reductase (hydroxyurea, [HU]) have been proposed as a new therapeutic strategy… Expand
Is this relevant?
1988
1988
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.
A phase 1 study of a new ribonucleotide reductase inhibitor, didox, was performed by administration of escalating doses of the… Expand
  • table II
  • table I
  • figure I
  • figure 2
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE